Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)

Lung Cancer ◽

10.1016/j.lungcan.2020.11.013 ◽

2021 ◽

Vol 152 ◽

pp. 7-14

Author(s):

Shun Lu ◽

Jie Wang ◽

Ying Cheng ◽

Tony Mok ◽

Jianhua Chang ◽

...

Keyword(s):

Lung Cancer ◽

Patient Population ◽

Chinese Patient ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Abstract CT114: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study

10.1158/1538-7445.am2018-ct114 ◽

2018 ◽

Cited By ~ 2

Author(s):

Yi-Long Wu ◽

Shun Lu ◽

Ying Cheng ◽

Caicun Zhou ◽

Jie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Population ◽

Chinese Patient ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)

10.1158/1538-7445.am2021-ct041 ◽

2021 ◽

Author(s):

Yuankai Shi ◽

Lin Wu ◽

Xinmin Yu ◽

Yan Wang ◽

Puyuan Xing ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Previously Treated

Download Full-text

Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer

Lung Cancer ◽

10.1016/j.lungcan.2021.12.009 ◽

2021 ◽

Author(s):

Jianhua Chang ◽

Yi-Long Wu ◽

Shun Lu ◽

Jie Wang ◽

Tony Mok ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Patient Population ◽

Patient Reported Outcomes ◽

Chinese Patient ◽

Small Cell ◽

Small Cell Lung ◽

Patient Reported ◽

Previously Treated

Download Full-text

Nivolumab versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3244996 ◽

2018 ◽

Author(s):

Yi-Long Wu ◽

Shun Lu ◽

Ying Cheng ◽

Caicun Zhou ◽

Jie Wang ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trial ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Patient Population ◽

Chinese Patient ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Previously Treated

Download Full-text

Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726215272.793539632 ◽

2017 ◽

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Randomised Controlled

Download Full-text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30641-0 ◽

2021 ◽

Vol 22 (2) ◽

pp. 198-211 ◽

Cited By ~ 2

Author(s):

Luis Paz-Ares ◽

Tudor-Eliade Ciuleanu ◽

Manuel Cobo ◽

Michael Schenker ◽

Bogdan Zurawski ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase

Download Full-text

Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial

The Lancet Respiratory Medicine ◽

10.1016/s2213-2600(21)00134-x ◽

2021 ◽

Author(s):

Jianxing He ◽

Chunxia Su ◽

Wenhua Liang ◽

Shidong Xu ◽

Lin Wu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Adjuvant Treatment ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Egfr Mutant

Download Full-text

Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic Non‒Small-Cell Lung Cancer: Brief Report on a Randomized, Open-label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

JTO Clinical and Research Reports ◽

10.1016/j.jtocrr.2020.100104 ◽

2020 ◽

pp. 100104

Author(s):

Rathi N. Pillai ◽

Suresh S. Ramalingam ◽

Meena Thayu ◽

Patricia Lorenzini ◽

Diana A. Alvarez Arias ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Phase 1B

Download Full-text

30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2020.10.517 ◽

2020 ◽

Vol 31 ◽

pp. S1428

Author(s):

Y. Shi ◽

L. Wu ◽

X. Yu ◽

P. Xing ◽

J. Zhou ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Phase Iii Study ◽

Previously Treated

Download Full-text

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text